Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

Jo N. Fleming1,*, Richard A. Nash2, D. O. McLeod1, David F. Fiorentino3, Howard M. Shulman4, M. Kari Connolly5, Jerry A. Molitor6, Gretchen Henstorf7, Robert Lafyatis8, David K. Pritchard1, Lawrence D. Adams1, Daniel E. Furst9, Stephen M. Schwartz1

1 Department of Pathology, University of Washington, Seattle, Washington, United States of America, 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 3 Department of Dermatology, Stanford University School of Medicine, Stanford, California, United States of America, 4 Clinical Research Division, Pathology Section, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Seattle, Washington, United States of America, 5 Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America, 6 Department of Rheumatology, Virginia Mason Medical Center, Seattle, Washington, United States of America, 7 Program in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 8 Rheumatology Section, Boston University School of Medicine, Boston, Massachusetts, United States of America, 9 Department of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, United States of America

Background. Scleroderma is an autoimmune disease with a characteristic vascular pathology. The vasculopathy associated with scleroderma is one of the major contributors to the clinical manifestations of the disease. Methodology/Principal Findings. We used immunohistochemical and mRNA in situ hybridization techniques to characterize this vasculopathy and showed with morphometry that scleroderma has true capillary rarefaction. We compared skin biopsies from 23 scleroderma patients and 24 normal controls and 7 scleroderma patients who had undergone high dose immunosuppressive therapy followed by autologous hematopoietic cell transplant. Along with the loss of capillaries there was a dramatic change in endothelial phenotype in the residual vessels. The molecules defining this phenotype are: vascular endothelial cadherin, a supposedly universal endothelial marker required for tube formation (lost in the scleroderma tissue), antiangiogenic interferon α (overexpressed in the scleroderma dermis) and RGSS, a signaling molecule whose expression coincides with the end of branching morphogenesis during development and tumor angiogenesis (also overexpressed in scleroderma skin. Following high dose immunosuppressive therapy, patients experienced clinical improvement and 5 of the 7 patients with scleroderma had increased capillary counts. It was also observed in the same 5 patients, that the interferon α and vascular endothelial cadherin had returned to normal as other clinical signs in the skin regressed, and in all 7 patients, RGSS had returned to normal. Conclusion/Significance. These data provide the first objective evidence for loss of vessels in scleroderma and show that this phenomenon is reversible. Coordinate changes in expression of three molecules already implicated in angiogenesis or anti-angiogenesis suggest that control of expression of these three molecules may be the underlying mechanism for at least the vascular component of this disease. Since rarefaction has been little studied, these data may have implications for other diseases characterized by loss of capillaries including hypertension, congestive heart failure and scar formation.

Citation: Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, et al (2008) Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype. PLoS ONE 3(1): e1452. doi:10.1371/journal.pone.0001452

INTRODUCTION

Progressive systemic sclerosis, or scleroderma, is an uncommon connective tissue disease characterized by autoimmunity, diffuse fibrosis[1] in the skin and internal organs, and a vasculopathy with intimal hyperplasia of muscular and elastic arteries[2,3]. Raynaud’s phenomenon, an excessive vasospastic reaction to cold or stress[4], precedes diagnosis of scleroderma by months or years[5], and is early evidence of the vasculopathy associated with scleroderma. The vasculopathy in scleroderma can result in non-healing ulcers, gangrene and digit loss[6], clinical features rarely encountered in primary Raynaud’s disease.

Further evidence of endothelial damage in scleroderma are findings by nail fold capillaroscopy[7]. Typical findings include giant capillaries, hemorrhages, avascular areas and neovascularization[8]. This morphology resembles malformed capillary beds formed in response to vascular endothelial growth factor[9] and could be the result of increased levels of vascular endothelial growth factor produced in response to ischemia resulting from vasospasm and intimal hyperplasia[10]. Increased levels of vascular endothelial growth factor (VEGF) are known to be present in scleroderma[11] and high levels of VEGF are normally associated with increased angiogenesis. Instead there appears to be a loss of capillaries. Unfortunately, the prevailing belief that there is loss of capillaries in scleroderma is based on findings in nail fold capillaroscopy and is dependent on seeing columns of blood. The ischemia caused by Raynaud’s phenomenon, especially coupled with malformations caused by high levels of VEGF could cause capillary collapse and could be misinterpreted as loss of capillaries since nail fold microscopy would be unable to identify unperfused capillaries. Definitive evidence for rarefaction, as opposed to loss of capillary blood flow or malformation of newly formed vessels,
Capillary rarefaction has been identified, to our knowledge, in only three other pathologic entities: congestive heart failure, granulation tissue and hypertension[13,14]. Some researchers have suggested that rarefaction may contribute to the characteristic elevation in peripheral resistance in hypertension[14]. Scleroderma patients can also have cardiac failure associated with pulmonary fibrosis and pulmonary hypertension[15,16] but a link has not been found between the rarefaction in scleroderma and that in cardiac failure, and scleroderma patients are, as a group, hypotensive[17] rather than hypertensive.

To investigate the vasculopathy associated with scleroderma we examined protein and mRNA molecules in endothelial cells and capillaries of skin biopsies from patients with diffuse cutaneous scleroderma and normal controls. In addition, we retrospectively studied skin biopsies from diffuse cutaneous scleroderma patients enrolled in a pilot study of the effect of high-dose immunosuppressive therapy and autologous hematopoietic cell transplantation (HDIT/HCT)[18]. After HDIT/HCT, these patients all experienced significant clinical improvement[19] including decrease in the dermal fibrosis[19,20] and the modified Rodnan skin score (MRSS) and an increase in overall function as measured by the modified Health Assessment Questionnaire Disability Index (MHAQ). We analyzed biopsies from these patients, both before and after treatment, and have demonstrated a correlation between changes in tissue expression of angiogenesis related molecules and capillary numbers.

**RESULTS**

**Scleroderma vessels lost normal endothelial markers and gained inflammatory markers**

Normal dermal endothelium is characterized by several characteristic immunohistochemical markers including: CD31, a common blood group antigen (Ulex europaeus lectin), von Willebrand factor, and VE cadherin[21]. The most widely used of these is CD31, which also stains leukocytes[22]. We found the expected vascular labeling of vessels in normal and scleroderma skin, with some positive leukocytes. Endothelium in capillary loops and precapillary arterioles in normal skin are also positive for enzymatic activity of endogenous alkaline phosphatase[23].

Figure 1 (A and B) depicts normal and scleroderma biopsies where serial sections have been stained with CD31 and Ulex europaeus lectin. In scleroderma skin a population of vessels have no luminal staining for Ulex europaeus lectin whereas normal skin has robust staining in all vessels. Von Willebrand factor, VE cadherin (Figure 1 C), and alkaline phosphatase all showed similar marked loss of luminal stain.

Immunohistochemical and histochemical stain quantification showed significant loss in vessels in scleroderma biopsies for Ulex europaeus lectin (p = 0.01), alkaline phosphatase (p = 0.002), VE cadherin (p = 0.008), and von Willebrand factor (p = 0.033) (Table 1 Section A). The difference in sample numbers tested for each marker is a function of scarcity of tissue and when the IHC was done. Some samples were very small and IHC was done for only a few markers. Endothelial markers were scored according to presence of positive and negative vessels. Numbers of biopsies with vessels that all had stain on the endothelial cells are expressed as number of positive biopsies per total n. All endothelial markers showed a decrease in expression in scleroderma except CD31.

We assessed the vasculature for signs of endothelial inflammation and summarized the quantitative results in Table 1 B. High endothelial venules have been described in dermal vessels of chronic dermatopathies and are considered a sign of chronic inflammation[24]. The high endothelial venule phenotype has endothelial nuclei projecting into the lumen with characteristic proteins on the endothelial surface that provide a specialized site for lymphocyte migration [25]. CD123, CD62P, and smooth muscle actin are among the proteins expressed on inflamed vascular lumens[26,27]. Scleroderma patients clearly had increased inflammatory markers of endothelial cells compared to normal controls. The endothelial cells in scleroderma were found to have significantly increased expression of CD123 (high endothelial venule, p = 0.0005) and smooth muscle actin (p = 0.000001) although CD62P did not show a significant difference (p = 0.49). CD123+ (high endothelial venules), and smooth muscle actin staining patterns are depicted in Figure 1 D and E respectively.
**Table 1.** Molecular markers of microvascular phenotype, inflammation and cell cycle in skin biopsies from scleroderma compared to controls.

| Type of molecular marker   | Normal #pos/n′ | Scleroderma #pos/n′ | P value † |
|----------------------------|-----------------|---------------------|-----------|
| **A. Endothelial markers** |                 |                     |           |
| Alkaline Phosphatase       | 4/4             | 0/8                 | 0.002     |
| VE Cadherin                | 4/6             | 0/10                | 0.008     |
| CD31                       | 13/13           | 13/13               | 1         |
| Von Willebrand Factor      | 3/3             | 1/7                 | 0.033     |
| Ulex Europaeus Lectin      | 10/14           | 3/14                | 0.01      |
| **B. Inflammatory endothelial markers** | | | |
| CD123 (high endothelial venules) | 1/12 | 12/16 | 0.0005 |
| VCAM1                      | 0/4             | 5/5                 | 0.007     |
| ICAM1                      | 0/3             | 5/5                 | 0.017     |
| CD62P                      | 0/7             | 1/7                 | 0.49      |
| Smooth muscle actin        | 0/15            | 12/12               | 0.000001  |
| **C. Other inflammatory markers** | | | |
| PAR2                       | 0/4             | 5/5                 | 0.007     |
| PSGL1                      | 0/7             | 8/8                 | 0.0001    |
| IL-1α                      | 0/6             | 7/7                 | 0.0005    |
| **D. Other markers**       |                 |                     |           |
| RGS5 in situ               | 0/5             | 7/8                 | 0.004     |
| Interferon α in situ (IFNA1 and IFNA2) | 0/6 | 9/9 | 0.0001 |
| CD123 (plasmacytoid dendritic cells) | 1/12 | 14/16 | 0.0000005 |
| STAT1                      | 0/7             | 7/10                | 0.006     |
| **E. Endothelial cell death (apoptosis)** | | | |
| Cleaved Caspase 3          | 0/7             | 0/17                | 1         |
| **F. Perivascular cell Turnover:** | | | |
| K67 Antigen                | 0/8             | 11/11               | 0.00001   |
| **G. Endothelial cell turnover** | | | |
| K67 antigen                | 0/7             | 0/17                | 1         |

†Data are numbers biopsies with positive immunohistochemical, lectin and in situ staining of skin biopsies over total number of biopsies available for staining.

While looking at high endothelial venules in scleroderma skin (above), we found a population of strongly CD123+ cells infiltrating the dermis. Scleroderma dermis had many CD123+ cells in the superficial horizontal plexus, significantly more than normal skin (p = 0.000005, Table 1D). CD123+ cells known as plasmacytoid dendritic cells are the primary producers of interferon α in the human body[37]. To look for the presence of interferon α mRNA expression we used IFNA1 and IFNA2 RNA in situ probes to look for expression of interferon α mRNA. 100% of Scleroderma patients were positive for interferon α and 0% of the normal had interferon α (p = 0.0001). Normal skin showed no detectable hybridization in the dermis and occasional faint hybridization in the epidermis whereas scleroderma tissue always expressed interferon α mRNA in the dermis and epidermis. The interferon α+ cells, probably plasmacytoid dendritic cells, were present next to small vessels in the superficial horizontal plexus in the upper dermis (Figure 2 B). In situ results were repeated 3 times and results were consistent.

To further confirm the presence of interferon α, we used staining for downstream markers of type 1 interferon activity. Canonical type 1 interferon signaling involves the binding of type 1 interferon (interferon α or β) to the type 1 interferon receptor, activation of the JAK/STAT pathway, and phosphorylation of STAT1[38]. Presence of phosphorylated STAT1 in the nucleus of cells STAT1 dimerization with another phosphorylated STAT and translocation into the nucleus. STAT1 phosphorylation was present in cellular nuclei in 7 of 10 scleroderma biopsies (depicted in Figure 2 C), but negative in all 7 normal controls tested (p = 0.006, Table 1 D).

**Scleroderma skin had an infiltrate of CD123+ cells, an increase in interferon α mRNA expression and downstream signaling markers of interferon**

To confirm the presence of interferon α, we used staining for downstream markers of type 1 interferon activity. Canonical type 1 interferon signaling involves the binding of type 1 interferon (interferon α or β) to the type 1 interferon receptor, activation of the JAK/STAT pathway, and phosphorylation of STAT1[38]. Presence of phosphorylated STAT1 in the nucleus of cells STAT1 dimerization with another phosphorylated STAT and translocation into the nucleus. STAT1 phosphorylation was present in cellular nuclei in 7 of 10 scleroderma biopsies (depicted in Figure 2 C), but negative in all 7 normal controls tested (p = 0.006, Table 1 D).

**Scleroderma skin had increased mRNA expression of RGS5 and no sign of endothelial death or proliferation**

The apparent loss of capillaries in scleroderma led us to look for increased expression of RGS5 mRNA. We found that both RGS5 mRNA expression was significantly increased in scleroderma (Table 1 D). RGS5 is a regulator of G protein coupled receptor signaling with cardiovascular properties[39] and specific association with arteries[40]. For as yet unknown reasons, RGS5 is expressed in pericytes that coat angiogenic vessels and appearance of this gene correlates with loss of the ability to branch[41]. RGS5 in situ probes showed <1RGS5+ cells in normal skin. The same probes hybridized with >10 cells per hpf cells in the 7 of 8 biopsies of scleroderma skin, both in a perivascular distribution, and scattered throughout the dermal matrix in cells that seem to be myofibroblasts. There was a strong signal in the epidermis of the scleroderma patient as well (Figure 2 D).

For the same reasons we looked at RGS5 we looked for direct evidence of endothelial cell death and/or signs that vessels were growing to replace the lost capillaries. To assess for signs of apoptosis, the tissue was examined for nuclear changes characteristic of apoptosis and stained for the apoptotic marker cleaved caspase 3 [42] (Table 1 E). Cleaved Caspase 3 staining is recorded unit (photomicrographs not shown). IL-1α activates complex pathways in endothelial cells, dramatically affecting function. PSGL1 is the high affinity counter receptor for selectins and is constitutively expressed on some kinds of inflamed endothelium [35]and PSGL1-selectin interactions play a role in homing and entry of inflammatory cells into sites of inflammation[36].
Scleroderma had a decreased numbers of capillaries

Finally, to confirm that rarefaction exists in scleroderma, we quantified the number of vessels present in normal and scleroderma skin biopsies. Vessel counts based on finding red blood cells can be misleading when vessels are collapsed; therefore we used the presence of CD31 to define vascular profiles. We compared average numbers of vessels per high power field between forearm skin sections from 21 scleroderma patients and 13 site-matched normal controls. To determine if blood vessels decrease during the course of disease, we measured biopsies from each patient group whose disease duration was 2 years or less, and compared vessel density to biopsies whose disease duration was five years or greater and compared both disease groups to normal vessel counts (Figure 3A). The numbers of vessels per high power field in scleroderma was virtually identical both early (2 years or less) and late in disease (5 or more years) and there was no statistically significant difference (p = 0.4). Vessel counts of normal controls differed significantly compared with both early (p = 0.02) and late (p = 0.04) scleroderma and showed that the number of total vessels was decreased overall in scleroderma (Figure 3 A). To approximate capillary numbers, profiles of vessels were counted in skin sections stained with an antibody for CD31. Profiles were defined as clusters of positive CD31 stained cells within the dermis with no central lumen visible (Figure 3B). To approximate the numbers of larger vessels and the remainder of capillaries we counted lumens in the same sections. Lumens were defined as clusters of CD31 stained cells with a central lumen clearly visible (Figure 3B). Comparison of lumens and profiles between controls and scleroderma (Figure 3C) show that profiles were significantly decreased in scleroderma (p = 0.009) whereas lumens were not (p = 0.18). This suggests that vascular loss in early diffuse scleroderma is in smaller vessels, likely representing capillaries.

Scleroderma endothelia regained a normal endothelial marker and lost inflammatory markers after HDIT/HCT treatment

Next we evaluated biopsies from patients with scleroderma who underwent HDIT/HCT. Our study of capillary counts, IHC and in situ study included biopsies from 7 patients at baseline and at a median of 5 (range 4–6) years after treatment. As noted in table 2, the patients from the clinical trial whose skin biopsies were evaluated for the effects of HDIT/HCT on the microvasculature, all experienced improvement in clinical assessment of scleroderma (results of clinical trial have been previously published) [19], including activities of daily life, stamina, energy, and shortness of breath. Each of the 7 patients also reported improvement in range of motion, hand flexion and reduction in skin tightening, and pathologically the degree of the dermal fibrosis improved [19].

We looked at endothelial phenotype, comparing endothelial marker expression by IHC, and found that alkaline phosphatase, Ulex europaeus lectin, and von Willebrand factor did not return to normal after HDIT/HCT. CD31 was consistently positive both before and after HDIT/HCT. VE cadherin stain was absent in a population of vessels in all baseline biopsies. No VE cadherin-negative vessels were present in 5 of 7 biopsies after HDIT/HCT (p = 0.01, Table 3A, see photomicrographs figure 4A and B for CD31 and VE cadherin).
CD123+ (high endothelial venules) endothelial cells significantly decreased \(p = 0.01\) after HDIT/HCT in scleroderma patients, although smooth muscle actin expression was not \(p = 0.08\).

**Interferon \(\alpha\) mRNA expression in scleroderma decreased after HDIT/HCT treatment**

Interferon \(\alpha\) mRNA \textit{in situ} hybridization, CD123 (plasmacytoid dendritic cells) and STAT1 were all significantly decreased after HDIT/HCT (Table 3C). At baseline, all 7 patients had markedly high transcript levels of interferon \(\alpha\) mRNA both in the dermis and epidermis whereas five of 7 patients after HDIT/HCT showed loss of RNA hybridization for interferon \(\alpha\) in the dermis and epidermis (\(p = 0.01\), see photomicrographs Figure 4C). The marker for plasmacytoid dendritic cells, CD123, present in all baseline biopsies preceding HDIT/HCT, was lost in 6 of 7 patients after HDIT/HCT (\(p = 0.01\)) To further confirm the loss of interferon \(\alpha\) expression, presence of nuclear phosphorylated STAT1 was decreased (\(p = 0.001\)) after HDIT/HCT (Table 3B). The decrease in signs of interferon \(\alpha\), CD123+ plasmacytoid dendritic cells and STAT1 may indicate that the interferon \(\alpha\) producing cells are destroyed or deactivated by treatment, and in the context of the capillary counts below have interesting vascular implications.

**After HDIT/HCT scleroderma skin had decreased mRNA expression of RG55 and no sign of endothelial death or proliferation**

RNA \textit{in situ} hybridization for RG55 at baseline shows that 6 of 7 scleroderma patients had increased positive cells (\(p = 0.0023\), Table 3C). After HDIT/HCT, all 7 biopsies had less than one per high power field (depicted in Figure 4D).

Biopsies before and after had numbers of perivascular cells in cell cycle greater than normal (\(p = 0.09\), Table 3D). Ki67 was not seen in endothelial cells before and after HDIT/HCT (\(p = 1\), Table 3E). IHC for cleavage of caspase 3 and histological analysis of the endothelial cells before and after HDIT/HCT showed very little cell death (\(p = 1\), Table 3F).

**After HDIT/HCT, capillary numbers increased in those patients who lost all interferon \(\alpha\) expression, and regained VE cadherin**

To demonstrate whether capillary counts increase after treatment, we quantified biopsies from the scleroderma patients who grew back capillaries at baseline and after HDIT/HCT. Patients after HDIT/HCT show significantly increasing capillary numbers (\(p = 0.015\), Figure 5). Most interesting, because of the mechanistic implications, is the correlation of the capillary numbers with VE cadherin and interferon \(\alpha\) expression. All 7 patients showed changes in interferon \(\alpha\) and VE cadherin in baseline biopsies. In the 5 patients where capillary counts increased, IHC for VE cadherin was positive in all vessels (Table 4). In the same patients where VE cadherin expression returned to normal, \textit{IFNA1} and \textit{IFNA2} \textit{in situ} hybridization (interferon \(\alpha\)) was undetectable (Table 4, see Figure 4C for photomicrographs).

**Late stage scleroderma did not resemble scleroderma after treatment**

Skin changes in scleroderma at a late stage of disease can include some softening and reduction of symptoms[43,44]. These late stage skin changes could be a potentially confounding factor for the scleroderma patients after HDIT/HCT since their disease duration spans 5 to 7 years after diagnosis. We therefore included as a final control, 4 skin biopsies from patients with a similar duration of disease (5–6 years from diagnosis). These biopsies were compared to the biopsies of the 7 patients after HDIT/HCT.
We compared the IHC results after HDIT/HCT with four patients whose disease duration is 5 years or longer. VE cadherin was negative in scleroderma of long duration, 4 of 4 Non-HDIT/HCT scleroderma patients of 5 years or greater scleroderma duration still have vessels that do not express VE cadherin. 4 or more years after HDIT/HCT however, 5 of 7 patients have regained all VE cadherin expression in biopsies (p = 0.007, Table 5A). VE cadherin expression has therefore returned only after HDIT and is not an artifact of late stage disease.

The CD123+endothelial cells (high endothelial venules) has resolved itself in 6 of 7 biopsies after HDIT/HCT, whereas Non-HDIT/HCT patients with similar (5 years or greater) disease duration all have CD123+ vessels with high endothelial morphology (p = 0.017, Table 5B). Similarly the expression of interferon α mRNA by in situ hybridization is undetectable in 5 of 7 biopsies, whereas 2of four late stage disease patients have interferon α+ cells in dermis (p = 0.047, Table 5C). The perivascular cells positive for CD123 are also increased in late stage patients but have disappeared in all but one of the post HDIT/HCT biopsies (p = 0.017, Table 5C). Loss of the expression of interferon α, absence of CD123+cells, as well as inflammation, appear also not to be an artifact of late stage disease but seem to be associated with HDIT/HCT. Limited amounts of available tissue prohibited us from obtaining results for RGS5.

Profile counts showed a significant increase (p = 0.025) in the average number of capillaries per hp in the five patients who grew back capillaries after HDIT/HCT, compared with Non-HDIT/HCT scleroderma of 5–6 years duration (Figure 5).

DISCUSSION

In this study, the most impressive changes in the dermis of scleroderma patients were rarefaction of capillary loops, loss of expression of VE cadherin, and the appearance of mRNA for interferon α and RGS5. While we also observed changes in other molecules, the changes in these three molecules are particularly relevant because they have all been reported to play possible critical roles in angiogenesis. We also report that after HDIT/HCT the above changes reverse, especially when increasing capillary counts are found in the tissue. We showed that these changes are unlikely to be the result of the natural history of scleroderma, and suggest that these findings may provide clues to the pathogenesis of this poorly understood disease.

An endothelial phenotype that lacks normal markers is a puzzle and to the best of our knowledge this is previously unreported. One extreme possibility is that endothelial cells no longer line the vessels. We do not think this is true. On two samples of normal and

### Table 2. Clinical and pathological findings after HDIT and HCT correlated with vessel counts.

| Patient # | Specimen Code # | Time after HDIT/HCT (years) | Before HDIT/HCT vessels count | After HDIT/HCT vessels count | Drop in MRSS after HDIT/HCT | Drop in dermal fibrosis after HDIT/HCT | Change in MHAQ score After HDIT/HCT |
|-----------|-----------------|----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------------------------|-------------------------------------|
| 9         | 0942            | 6                          | 6.8                         | 7.7                         | 16                          | 3                                    | 1 to 0                              |
| 11        | 1105            | 5                          | 6.14                        | 7.9                         | 30                          | 5                                    | 2.5 to 0                            |
| 12        | 1226            | 1                          | 8.2                         | 8                           | 1                           | 0.75 to 0                            |
| 18        | 1888            | 5                          | 5.2                         | 12                          | 18                          | 3                                    | 2.125 to 1.5                        |
| 22        | 2218            | 4                          | 6.59                        | 3.43                        | 22                          | 4                                    |                                     |
| 24        | 2435            | 4                          | 5.09                        | 8.78                        | 6                           | 4                                    | 2.875 to 2.375                      |
| 26        | 2622            | 4                          | 5.7                         | 4.4                         | 34                          | 4                                    | 2.875 to 0.125                      |

For each of the clinical parameters assessed, post-HDIT/HCT values were compared to pre-HDIT/HCT (baseline) values at the last time point in each of several post-HDIT/HCT time windows.

1. Reported finger contractures as the only indication of evidence of scleroderma post HDIT/HCT.
2. No clinical or pathologic data is available for the first 4 years post HDIT/HCT. Patient subsequently underwent right lower lobectomy 4 years 9 months post HDIT for squamous cell carcinoma.
3. Developed pulmonary hypertension.
4. Did not have increased capillary counts in post HDIT/HCT biopsies.
5. Did not have a count done on the one year biopsy and clinical data was not available for four year biopsy.

Abbreviations: mRSS—Modified Rodnan Skin Score for dermal fibrosis; MHAQ—modified Health Assessment Questionnaire Disability Index

### Table 3. Molecular markers of microvascular phenotype, inflammation and cell cycle in skin biopsies from scleroderma before and after HDIT/HCT

| Type of molecular marker | Before HDIT/HCT # | After HDIT/HCT # | P value
|--------------------------|-------------------|------------------|-----------
| A) Endothelial markers   |                   |                  |           |
| Alkaline Phosphatase     | 0/7               | 0/7              | 1         |
| VE Cadherin              | 0/7               | 5/7              | 0.010     |
| CD31                     | 6/7               | 7/7              | 0.49      |
| Von Willebrand Factor    | 1/7               | 4/7              | 0.13      |
| Ulex Europeus Lectin     | 2/7               | 3/7              | 0.49      |
| B Inflammatory           |                   |                  |           |
| CD123 (high endothelial venules) | 6/7 | 1/7 | 0.01 |
| Smooth muscle actin      | 5/5               | 2/5              | 0.08      |
| C Other :                |                   |                  |           |
| RGS5 in situ             | 6/7               | 7/7              | 0.0023    |
| Interferon α in situ (IFNA1 and IFNA2) | 7/7 | 2/7 | 0.01 |
| STAT1                    | 6/6               | 0/6              | 0.001     |
| CD123 (plasmacytoid dendritic cells) | 6/7 | 1/7 | 0.01 |
| D Perivascular cell Turnover: |             |                  |           |
| K67 Antigen              | 7/7               | 5/7              | 0.01      |
| E Endothelial cell turnover |            |                  |           |
| K67 antigen              | 0/7               | 0/7              | 1         |
| Cleaved Caspase 3        | 0/7               | 0/7              | 1         |

1. Data are numbers of biopsies with positive immunohistochemical, lectin and in situ staining of skin biopsies over total number of biopsies available for staining.
2. P values were calculated with Fisher’s exact test using 2 x 2 frequency tables.
3. doi:10.1371/journal.pone.0001452.t003
scleroderma skin, we performed electron microscopy (data not shown). The luminal cells of these samples lacked features of other cell types, which can, under some circumstances, form a lining. For example, we looked for the microplicated surface of macrophage or the altered polarity and microfilaments characteristic of smooth muscle cells and found none of these characteristics in the luminal cells in scleroderma vessels. One could speculate a variety of mechanisms to explain endothelial cells without normal markers: 1) differentiation of a cell type other than normal dermal microvascular endothelial cells into an endothelial-like morphology, which replaced the dead endothelial cells early in disease; 2) circulating precursors from other endothelial lineages (e.g. sinus, lymphatic) replace the normal dermal endothelial cells into an abnormal state and/or cause chronic inflammation; 3) activating autoantibodies to endothelial cells or other circulating factors, which cause them to differentiate into an abnormal state and/or cause chronic inflammation; 4) a pathological cell type on the endothelial cell expressome, or 5) an underlying mechanism or structural abnormality existent in scleroderma endothelial cells responsible for some part of the vascular abnormality similar to that found in the children of patients with malignant hypertension[45].

The bulk of capillaries in the skin are capillary loops branching from the superficial horizontal plexus into the rete pegs and consist of a single layer of endothelium with a few pericytes all above the border of the rete ridge[46]. This is a highly specific structure, optimized to improve thermal exchange. Our data showed that capillary loops, are lost from scleroderma skin at a very early stage. This loss was associated with a dramatic and unusual loss of expression of markers used to define the endothelial cell lineage including VE cadherin. We found significant loss of the smallest vessels in the baseline scleroderma skin biopsies (all 2 years or less from diagnosis). The low number of vessels appeared to remain constant at all stages of disease. After HDIT/HCT the endothelial marker which did return to normal in 5 of 7 patients, VE cadherin, is a calcium dependent cell adherens junction protein responsible during development for aggregation of cells and formation of endothelial tubes[47]. The loss of VE Cadherin in baseline scleroderma and the reappearance of VE cadherin after HDIT/HCT may be significant in terms of the angiogenic potential of the skin, since the same 5 patients whose VE cadherin expression returned to normal also increased the numbers of capillaries present in their skin.

RGS5 mRNA expression was reversed in all 7 patients after treatment, and did not correlate specifically with regeneration of capillaries, since two of the seven did not increase average skin capillary numbers. This indicate that decreased RGS5 expression after HDIT/HCT is insufficient to regenerate capillaries by itself, but like the VE Cadherin data may suggest that some form of vasostatic process in scleroderma inhibited any angiogenic response prior to treatment. The hypothesis exists that part of pathogenesis of scleroderma is circulation of an endothelial toxic agent, loss of circulating endothelial precursors or some other less specified dysregulation of the angiogenic pathway[48,49]. How
Intriguingly, the two patients interferon expression signature has been described in autoimmune connective tissues diseases, including scleroderma[56-58]. We found CD123+ interferon-producing cells[59] at the superficial horizontal plexus where the bulk of capillaries would be, and where angiogenesis should be taking place. Furthermore, increased STAT1 expression in the same areas confirms the presence of an interferon response. The evidence that expression of interferon α mRNA was decreased 5 of 7 patients undergoing HDIT/HCT combined with the unexpected observation of vascular regeneration suggest that an antiangiogenic state may have been reversed by this treatment. We are unaware of any other study that has shown reversible rarefaction in any disease. Intriguingly, the two patients interferon α expression was still present were the same two patients that did not grow new capillaries and had vessels negative for VE Cadherin.

Table 4. Increased vessel number following HDIT/HCT is correlated with return of normal immunohistochemical expression of VE cadherin and α interferon in skin biopsies in late stage scleroderma

| Patient # | Change in Average vessel/hpf | Time after HDIT/HCT (years) | Before HDIT/HCT | After HDIT/HCT | After HDIT/HCT | After HDIT/HCT |
|-----------|-----------------------------|-----------------------------|----------------|----------------|----------------|----------------|
| 9         | +0.9                        | 6                           | neg            | pos            | pos            | neg            |
| 11        | +1.8                        | 5                           | neg            | pos            | pos            | pos            |
| 12        | +2.6                        | 4                           | neg            | pos            | pos            | neg            |
| 18        | +7                          | 5                           | neg            | pos            | pos            | neg            |
| 22        | −3.2                        | 4                           | neg            | pos            | neg            | pos            |
| 24        | +3.7                        | 4                           | neg            | pos            | pos            | neg            |
| 26        | −1.3                        | 4                           | neg            | pos            | neg            | pos            |

*these 2 patient’s skin biopsies had decreased numbers of vessels

Table 5. Scleroderma Patients after HDIT/HCT with Capillary Regeneration, Compared with Patients of Similar Disease Duration

| Type of molecular marker | After HDIT/HCT # | Same disease duration # | P value |
|--------------------------|-----------------|-------------------------|---------|
|                          | pos/n1         | pos/n2                  |         |
| A) Endothelial Markers   |                 |                         |         |
| CD31                     | 7/7             | 4/4                     | 1       |
| VE Cadherin              | 5/7             | 0/4                     | 0.007   |
| B Inflammatory markers   |                 |                         |         |
| CD123 (high endothelial venules) | 0/5           | 3/3                     | 0.017   |
| C. Other Markers         |                 |                         |         |
| Interferon α in situ (IFNA1 and IFNA2) | 0/5           | 2/2                     | 0.047   |
| CD123 (plasmacytoid dendritic cells) | 0/5           | 3/3                     | 0.017   |

*Data are numbers of biopsies with positive immunohistochemical, lectin and in situ staining of skin biopsies over total number of biopsies available for staining.

Existing observations suggest that vascular disease is paramount in the pathogenesis of scleroderma[60,61]. Certainly vasospasm, as in Raynaud’s, is a frequent, though not a clearly obligatory precursor to disease. It is also possible that rarefaction precedes diagnosis of scleroderma by many years and our data suggest this may be the case. There are no objective data of which we know showing elevated levels of cell death or apoptosis in any phase of this disease. Suggestions that apoptosis and rarefaction occur during active disease have been based on studies showing the presence of circulating factors able to kill endothelial cells in culture[62] but the relevance to endothelial death in vivo is not known. Similarly, endothelial autoantibodies in scleroderma have been classified as anti-microvascular and are cited by some as a cause of vessel loss[63,64]. Once again, these data are limited to in vitro studies that may not represent in vivo phenomena. Our studies were of skin biopsies only and, especially in the context of the HDIT/HCT trial, fresh tissue samples were limited. Given the number of possible circulating factors which may cause the death of endothelial cells or prevent their growth, it may be best in future studies to approach this problem with a discovery biology approach (such as proteomics or gene expression arrays) rather than a direct method. Also, since the natural history of the disease tends to decrease the levels of inflammatory factors as the disease moves from an inflammatory to a chronic sclerotic phase, it may not be possible to find significant differences without much larger numbers of patients than we have in this study. A larger study is underway and, given the clinical success of this one, and we may be able to assess antiendothelial antibodies and other circulating factors together with a more detailed assessment of cell death. We found no evidence of ongoing endothelial cell death in the scleroderma skin compared with normal controls, and must conclude that any endothelial cell death in scleroderma, implied by capillary rarefaction, must be an early or episodic event in scleroderma. To further support the suggestion that capillaries are lost very early, we found no evidence that capillary numbers continue to drop over time in scleroderma.

If active capillary loss is occurring, there should be angiogenesis and vessel replacement in the superficial horizontal plexus at the post capillary venule[65] involving endothelial proliferation[66]. The pattern of malformed vessels seen in nail beds is, in fact, reminiscent of patterns of angiogenesis seen with localized over expression of VEGF[67,68]. Evidence published by others that circulating and local VEGF is increased in scleroderma has led to a dilemma. How can elevated VEGF be correlated with loss of the microvasculature? In the scleroderma dermis we see no evidence of endothelial replication in the superficial horizontal plexus...
suggesting that there is no angiogenic response but we have not found a good explanation for this conundrum.

A possible mechanism for the return of capillaries, consistent with the effects of HDIT/HCT is that endothelial precursor cells are required for angiogenesis[69–71]. An infusion of the CD34-selected hematopoietic cell graft may have therefore contributed to the re-capillarization. Unfortunately at the time of the HDIT/HCT study, samples were not taken to analyze levels of circulating endothelial cells. In future studies it may be an excellent way to confirm that endothelial cells have returned to normal in scleroderma. Alternatively, and in our opinion more likely, HDIT/HCT is immunosuppressive and may be ablating some cell that inhibits endothelial regeneration or produces a factor or factors that inhibit endothelial cell regeneration. HDIT/HCT treatment has been investigated for other autoimmune diseases besides scleroderma including systemic lupus erythematosus and multiple sclerosis. It has been previously reported that there was recovery of CD4+ T cell counts after HDIT/HCT at 2 years after HDIT/HCT. However, sustained responses were observed in 63% of patients at a median of 4 years[72]. Immune recovery after HDIT/HCT is associated with increasing thymic-derived naive CD4+ T cells with a decrease in memory T cells, an increase in regulatory T cells, and broader clonal diversity than was present before HDIT/HCT[72–74] These late immune changes support the conclusion that sustained responses may have resulted from the immunomodulatory effects of HDIT/HCT in addition to the early immunosuppression and depletion of autoreactive T cells. After HDIT/HCT, we observed that those patients who grew back capillaries were different from scleroderma of long duration. The patients who received HDIT/HCT had more capillaries and also lost interferon α expression, and regained all VE cadherin expression, whereas the scleroderma in late stages did not. The interferon expression and CD123+ cells are interesting in this context since one of the functions of the plasmacytoid dendritic cell is the breaking of tolerance[37], and it may be associated with some of the changes in T cell populations. The high levels of interferon α support the hypothesis that plasmacytoid dendritic cells may be part of the pathogenesis of scleroderma. Interferon α is antiproliferative in vivo[75]. The high local levels of interferon α in scleroderma skin may therefore be preventing the formation of new capillaries directly.

In conclusion we propose that rarefaction is an early and possibly “pre-diagnosis” event in scleroderma. This capillary loss is associated with a change in endothelial phenotype of the remaining vessels that has not been previously described. The phenotype of these residual vascular structures appears to be mildly inflammatory but not apoptotic, with no sign of endothelial replication or replacement. We hypothesize that the presence of interferon α, the loss of VE cadherin and the presence of RGS5 are involved in the process which appears to keep the vessels static and produce fibrosis in this poorly understood disease. We report regeneration of capillaries and resolution of the non-angiogenic phenotype after HDIT/HCT. Our studies were somewhat limited by the retrospective nature, however, future planned studies of this autologous protocol and an allogenic protocol will include capillaroscopic, ultrasound and MRI microvascular assessment in a subset of patients in the hope of defining these microvascular changes and assessing clinical importance. Regulation of VE cadherin expression, function of RGS5 producing smooth muscle, appearance of interferon α at other sites of vascular rarefaction, and the apparent ablation by HDIT/HCT of some cell involved in the inhibition of angiogenesis are obviously intriguing targets for continued study. Rarefaction itself is not well studied in the known examples of cardiac failure, hypertension and regression of granulation tissue. Our studies may provide new clues to the more general problem of capillary loss.

**METHODS**

**Patients in the study**

All tissue used in this study were biopsies supplied in collaboration with Stanford University, the University of California San Francisco, Boston University, Fred Hutchinson Cancer Research Center, and the University of Washington, collected and analyzed according to Institutional Review Board approved protocols for human study at each respective institution. Normal controls (Table 6) and scleroderma patient biopsies (Table 7) were supplied as sets of formalin fixed paraffin embedded blocks or slides.

**HDIT/HCT**

The clinical trial of HDIT/HCT for patients with scleroderma has been previously described[19]. Briefly, hematopoietic stem cells were mobilized with granulocyte colony stimulating factor, harvested from the peripheral blood by leukapheresis and then CD34-selected. HDIT/HCT consisted of total body irradiation (800 cGy) with partial lung shielding, high-dose cyclophosphamide (120 mg/kg) and antithymocyte globulin (Pfizer Inc., New York, NY). After HDIT/HCT, patients were transplanted with the autologous CD34-selected hematopoietic cell graft.

**Histochimistry**

Tissue was stained with hematoxylin & cosin and Movat’s pentachrome according to standard protocols. In addition to these two stains, tissue was stained for endogenous alkaline phosphatase. Briefly, the sections were cut, dewaxed with xylene and rehydrated with ethanol series prior to pretreatment with 100 mM glycine and 0.3% Triton X-100. They were then allowed to develop overnight in 3-Bromo-4-Chloro-3′-Indolylphosphate p-Toluidine Salt/Nitro-Blue Tetrazolium Chloride (Roche). Counterstain is Nuclear Fast Red (Vector Labs). The slides were mounted with Aquamount (VWR Scientific).

**Immunohistochemistry (IHC)**

Antibodies are listed in Table 8 with dilution, manufacturer and clone number and secondary antibody.

**In-lab IHC**

Briefly, our protocol for IHC is as follows: paraffin sections were dewaxed and rehydrated prior to antigen retrieval using microwave method in sodium citrate pH 6.0. Slides were placed in citrate buffer and microwaved for 20 minutes on low power, allowed to cool and placed in blocking buffer for 30 minutes, incubated with primary antibody overnight at 4°C, then washed and incubated with biotinylated secondary antibody (Vector Labs Universal horse anti-mouse/rabbit/goat #BA-1400 or Vector Labs Universal horse anti-mouse/rabbit #BA-1400) for 30 minutes. After secondary antibody, the slides were washed and incubated for 30 minutes with avidin biotin complex reagent (Vector Labs Universal horse anti-mouse/rabbit/goat #BA-1400) for 30 minutes. After incubation with secondary antibody, the slides were then counterstained with methyl green, dehydrated in ethanol series, cleared in xylene and mounted with Permount (Fisher Scientific).

**Phenopath IHC**

Immunohistochemistry done at Phenopath Labs (www.phenopath.com for their established protocols) is indicated in Table 8, along with protocols optimized for each antibody.
The protocol for RNA in situ including construction and amplification of probe was based on the protocol in the Roche DIG application manual[76]. Proteinase K digestion was performed at a concentration of 5 mg/mL for 20 minutes. Probe concentrations were 1 ng/uL and hybridizations were performed at 42°C overnight. Post hybridization washes followed this protocol: low stringency 4×15 minutes at 37°C, then high stringency 2×30 minutes at 55°C. Detection with alkaline phosphatase was performed with anti DIG Fab (Roche) at a dilution of 1:500 and the chromogen used was Vector Red (Vector Labs).

RNA Probe generation

Probe for RGS5 were made from plasmids with a 1.7 kb fragment of human RGS5 long previously characterized and published by us[40]. A 1.7 kb segment of DNA containing IFNA1 and a 2.2 kb segment for IFNA2 were amplified from a human Sanger DNA library clone (#RP11-354P17 GenBank accession #AL353732). The plasmids were subcloned using the Stratgene pPCRScriptamp kit. In vitro transcription was performed with DIG RNA labeling kit (Roche) and RNA was isolated (Agilent low RNA input fluorescent linear amplification kit protocol, 2006 version 4, page 19). Standard controls using sense RNA probes were run at the same concentration as the antisense probe with each experiment and showed no specific signal. Positive and negative tissue controls were included in every experiment as well to confirm signal. Standard blast searches were done for the DNA segments amplified and no major non-specific cross reactivity was found to other human DNA. Blast searches were done against the other interferon genes. Minor similarity found between interferon α genes and IFNW. No similarity was found between the interferon α genes and IFNB or IFNG.

Scoring methodology

All high power fields are at a magnification of 20×.

**Endothelial markers** Platelet endothelial cell adhesion molecule 1 (CD31) yielded a predictable staining pattern for all three groups of patients, and was used as a control for the other endothelial markers including von Willebrand factor, vascular

### Table 6. Age, sex and anatomic location of skin biopsies from normal controls

| Patient# | Age | Sex | Biopsy Location |
|----------|-----|-----|-----------------|
| 1        | un  | un  | scalp           |
| 2        | un  | un  | un              |
| 3        | un  | un  | scalp           |
| 4        | 45  | F   | forearm         |
| 5        | un  | un  | un              |
| 6        | un  | un  | scalp           |
| 7        | un  | un  | scalp           |
| 8        | un  | un  | breast          |
| 9        | un  | un  | abdomen         |
| 10       | un  | un  | breast          |
| 11       | 50  | F   | forearm         |
| 12       | 46  | F   | forearm         |
| 13       | 51  | F   | forearm         |
| 14       | 41  | M   | forearm         |
| 15       | 41  | F   | forearm         |
| 16       | 64  | F   | forearm         |
| 17       | 36  | M   | forearm         |
| 18       | 40  | F   | forearm         |
| 19       | 59  | F   | arm             |
| 20       | 47  | F   | posterior shoulder |
| 21       | 73  | F   | lateral neck    |
| 22       | 37  | F   | arm             |
| 23       | 54  | F   | posterior neck  |
| 24       | un  | un  | thigh           |

**Table 7. Age, sex, disease subtype and duration and anatomic site of skin biopsies of scleroderma patients**

| Patient# | Age | Sex | Disease Type | Biopsy Location | Disease Duration |
|----------|-----|-----|--------------|-----------------|-----------------|
| 1a       | 47  | F   | Diffuse      | Forearm         | 1 year          |
| 1b       | 48  |    |              |                 | 2 years         |
| 1c       | 51  |    |              |                 | 5 years         |
| 2a       | 44  | F   | Diffuse      | Forearm         | 1 year          |
| 2b       | 46  |    |              |                 | 3 years         |
| 2c       |    |    |              |                 | Back            |
| 2d       | 48  |    | Diffuse      | Forearm         | 5 years         |
| 3        | 47  | M   | Diffuse      | Forearm         | 1 year          |
| 4a       | 44  | F   | Diffuse      | Forearm         | 1 year          |
| 4b       |    |    |              |                 | Upper Arm       |
| 5        | un  | M   | Diffuse      | unn             | unn             |
| 6        | 51  | F   | Diffuse      | Forearm         | 1 year          |
| 7        | 33  | M   | Diffuse      | Forearm         | 1.5 years       |
| 8        | 35  | M   | Diffuse      | Forearm         | 16months\&s14year |
| 9        | 44  | M   | Diffuse      | Forearm         | 6 months        |
| 10       | 28  | F   | Diffuse      | Forearm         | 2.5 years       |
| 11       | 71  | F   | Diffuse      | Forearm         | 6 months        |
| 12       | 33  | F   | Diffuse      | Forearm         | 1.5 years       |
| 13       | 56  | F   | Diffuse      | Forearm         | 8 months        |
| 14       | 46  | F   | Diffuse      | Forearm         | 8 months        |
| 15       | 32  | F   | Diffuse      | Forearm         | 10 months       |
| 16       | 44  | F   | Diffuse      | Forearm         | 7 months        |
| 17       | 47  | F   | Diffuse      | Forearm         | 2.5 years       |
| 18       | 39  | F   | Diffuse      | Forearm         | 6 years         |
| 19       | 55  | F   | Diffuse      | Forearm         | 9 months        |
| 20       | 40  | M   | Diffuse      | Forearm         | 16months\&s14year |
| 21       | 44  | F   | Diffuse      | Forearm         | 6 months        |
| 22       | 45  | F   | Diffuse      | Forearm         | 5 years         |
| 23       | un  | un  | Diffuse      | Upper Arm       | un              |
| 24       | 43  | F   | Diffuse      | Forearm         | 15 months       |
| 25       | 37  | F   | Diffuse      | Upper arm       | 7 months        |
| 26       | 50  | F   | Diffuse      | Forearm         | 16months\&s14year |
| 27       | 46  | F   | Diffuse      | Upper arm       | 11 months       |
| 28       | 40  | F   | Diffuse      | Forearm         | 2 years         |
| 29       | 55  | F   | Diffuse      | Forearm         | 2 years         |
| 30       | 36  | M   | Diffuse      | Thigh           | 15 months       |

**Abbreviations** un = unavailable at this time

doi:10.1371/journal.pone.0001452.t007

doctoralı 1371/journal.pone.0001452.t006

Vessel Recovery in Scleroderma
endothelial (VE) cadherin, alkaline phosphatase and Ulex europaeus lectin. Serial biopsies were stained with all 5 markers and vessels (identified as clusters of cells positive for CD31) were compared. If vessels were found that had CD31 stain but lacked another marker in a serial section, the biopsy was scored as negative for that marker. The observed negative and positive were recorded in 2×2 frequency tables.

**RGS5 Stain score** Normal biopsies hybridized with RGS5 probes showed 0-1 perivascular cells per high power field. Slides that had more than 2 positive cells per high power field were considered positive. Positive slides always had increased perivascular expression, and some had many cells positive in the dermal matrix. Negative and positive were recorded in 2×2 frequency tables.

**Interleukin-3 receptor subunit alpha (CD123)** A high endothelial venule phenotype, smooth muscle actin and P selectin (CD62P) stain score Biopsies were examined for presence or absence of lumens of blood vessels with endothelial cells labeling with CD123, smooth muscle actin and CD62P. Biopsies were scanned until positive vessels were located or until entire biopsy had been examined. Biopsies with positive vessels were recorded as positive. Negative and positive were recorded in 2×2 frequency tables.

**Interferon α score** Biopsies were scored according to the presence or absence of positive stain anywhere in biopsy. Biopsies with any stain color were scored as positive. Negative and positive were recorded in 2×2 frequency tables.

**Vascular cell adhesion molecule 1 (VCAM1), Interleukin adhesion molecule 1 (ICAM1), p selectin glycoprotein ligand 1 (PSGL1), Proteinase activated receptor 2 (PAR2), Ki67 antigen (Ki67), CD123 (plasmacytoid dendritic cells), and cleaved caspase 3 stain score** The observed negative and positive were recorded in 2×2 frequency tables.

**Table 8. Antibodies used for immunohistochemical analysis of skin biopsies.**

| Antibody                                      | Manufacturer          | Clone          | Pretreatment | Dilution | Secondary/Kit          |
|-----------------------------------------------|-----------------------|----------------|--------------|----------|------------------------|
| Signal transducer and activator of transcription 1 (STAT1) | CellSigTech          | Tyr701, 5BD6   | Citrate/heat | 1:200    | Biomouse/rabbit Elite  |
| P Selectin (CD62P)                            | Abcam                 | AK-6           | Citrate/heat | 1:500    | Biomouse/rabbit Elite  |
| P Selectin glycoprotein ligand 1 (PSGL1)      | Abcam                 | 3E2.25.5 PL1   | Citrate/heat | 1:200    | Biomouse/rabbit Elite  |
| Interleukin-1alpha (IL-1α)                    | R&D Systems           | Lot #AA801     | Citrate/heat | 5 ug/mL  | Biomouse/rabbit/Goat Elite |
| Vascular endothelial (VE) Cadherin            | Novocastra            | BV6            | Citrate/heat | 1:100    | Vector Biomouse Elite  |
| Platelet endothelial cell adhesion molecule 1 (CD31) | Novocastra            | IA10           | EDTA         | 1:400    | Mouse/Envision         |
| Ulex europaeus lectin                        | Vector                | N/A            | Pronase      | 1:200    | Elite SA (no secondary) |
| Interleukin 3 receptor subunit alpha (CD123)  | DAKO                  | 7G3            | PXXIV        | 1:250    | Mouse/Envision         |
| smooth muscle actin                          | DAKO                  | IA4            | Pronase      | 1:250    | Mouse/Envision         |
| Protease activated receptor 2 (PAR2)          | Zymed                 | Sam11          | None         | 1:500    | Mouse/Envision         |
| Intercellular adhesion molecule 1 (ICAM1)     | Chemicon              | WCam1          | Citrate/heat | 1:200    | Mouse/Envision         |
| Vascular cell adhesion molecule 1 (VCAM1)     | R&D Systems           | BBA19          | EDTA         | 1:1000   | Vector BioGoat/Elite   |
| Ki67 antigen (Ki67)                           | DAKO                  | MIB-1          | Citrate/heat | 1:200    | Mouse/Envision         |
| Cleaved caspase 3                            | Cell Sig Tech         | #9661          | EDTA         | 1:200    | Vector BioGoat/Elite   |
| Von Willebrand factor                        | DAKO                  | M0616          | Pronase      | 1:100    | Mouse/Envision         |

Detection for all IHC performed using 3,3′-diaminobenzidine (DAB).

1 In Lab IHC
2 Phenopath IHC
3 doi:10.1371/journal.pone.0001452.t008

Capillary counts

For quantification purposes, we have used site-matched skin biopsies, since capillary loops change in number from site to site. Biopsies of normal, scleroderma and disease controls were stained with CD31. Photographs of entire biopsy to be counted were taken at 20× with an Olympus microscope and Spot camera. Two separate blinded investigators counted the same set of photographs and data are averages of the two counts. “Profiles” are defined as CD31 stained vessels without a central lumen “Lumens” are defined as CD31 stained vessels with central lumens. “Vessels” are defined as the sum of lumens and profiles.

Statistics

The stain scores for IHC and RNA in situ hybridization were recorded as frequency data and were analyzed for significance using Fishers Exact Significance test. Frequency data were obtained according to above scoring systems and 2×2 tables were used to record differences between groups. P values were calculated with one tailed probability value. Capillary quantification is a continuous variable and was therefore tested for significance using the students’ t test for independent variables. Values of p<0.05 were considered significant. Standard error was calculated with the standard deviation divided by the sq root of the N.
ACKNOWLEDGMENTS

Many people contributed to this study, too many to mention here, but we would like to specifically acknowledge Allen Gown and Phenopath Labs for the work they did on the contracted immunohistochemical staining, Andrew, Edowu, Lee, and Jeff for many tedious hours behind the microscope, the technical staff and histological core in Brotman building at the University of Washington.

REFERENCES

1. Jimenez SA, Hiraya E, Varga J (1996) Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am 22: 647–674.
2. LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22: 675–694.
3. Sapadin AN, Esser AC, Fleischmajer R (2001) Immunopathogenesis of scleroderma—evolving concepts. Mt Sinai J Med 68: 235–242.
4. Handa R, Kumar U, Pandey RM, Aggarwal P, Biswas A, Wali JP (2002) Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 138: 109–116.
5. Grunsvitz M, von den DF, Kellner I, Horstmann OP, Sterry W (1992) Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 27: 169–177.
6. Nystedt S, Ramakrishnan V, Sundelin J (1996) The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem 271: 14910–14915.
7. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, et al. (2002) High-resolution of dermal fibrosis. Arthritis Rheum 54: 1982–1986.
8. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, et al. (2000) Pulmonary fibrosis in systemic sclerosis. In: Clements PJ, Furst DE, eds (2003) Systemic Sclerosis. Los Angeles: Lippincott Williams & Wilkins. pp 129–150.
9. Carpentier PH, Maricq HR (1990) Microvascularity in systemic sclerosis. Rheum Dis Clin North Am 16: 75–91.
10. Chou JJ, Min DJ, Choi MN, Min SY, Kim SJ, et al. (2003) Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 30: 1529–1535.
11. Shore AC (2000) Capillaroscopy and assessment of capillary pressure. British J Dermatol 104: 521–529.
12. Lozier AC, LeRoy EC, Black CM (2003) Pulmonary Vascular Involvement in Systemic Sclerosis. In: Clements PJ, Furst DE, eds (2003) Systemic Sclerosis. Los Angeles: Lippincott Williams & Wilkins. pp 109–116.
13. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, et al. (2000) Rarefaction of skin capillaries in normotensive offspring of individuals with systemic sclerosis—evolving concepts. Mt Sinai J Med 68: 233–242.
14. D'Andrea MR, Gogolin AJ, Anfrade-Gordon P (2000) Localization of proteinase-activated receptors-1 and -2 in human mast cell: indications for an amplified mast cell degradation cascade. Biochem Biophys Acta 1497: 45–50.
15. Facchetti F, Vermi W, Mason D, Colonna M (2003) The plasmacytoid monocyte/interferon producing cells. Microcirculation 10: 471–478.
16. Antonios TF, Singer DR, Markandu ND, Morriss PR, McDuifie M, et al. (2006) Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med 203: 907–917.
17. Sperandio M, Smith ML, Forlow SB, Olson TS, Xia L, et al. (2003) P-selectin glycoprotein ligand-1 mediates L-selectin-dependent leukocyte rolling in venules. J Exp Med 197: 1353–1365.
18. Goodbourn S, Didcock L, Randall R (2000) Interferon: cell signalling, immune modulation, antiviral response and virus countermeasures. Journal of General Virology 81: 2341–2364.
19. Braverman IM (2000) The cutaneous microcirculation. J Investig Dermat Symp Proc 5: 3–9.
20. Wieladek Y, Viglaih G, Huber P (2006) Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 16: 55–59.
21. Dieterle O, Dietler JH, Scheid A, Acker T, Hirth A, et al. (2000) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 87: 109–116.
22. Liu X, Zha S, Wang T, Hummers I, Wigley FM, et al. (2005) Paclitaxel Modulates TGFβ Signaling in Scleroderma Skin Grafts in Immunodeficient Mice. J Immunol 174: 5684–5692.
23. Singh KK, Gutman M, Bucana CD, Sanchez R, Llanas N, et al. (1995) Interferon alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 92: 4562–4566.

Author Contributions

Conceived and designed the experiments: SS JF DF. Performed the experiments: JF DM. Analyzed the data: JF GH HS. Contributed reagents/materials/analysis tools: JF RN DF MC JM GH RL HS. Wrote the paper: SS JF RN JM RL DP LA DF HS.
51. Minasian LM, Motzer RJ, Glick I, Mazumdar M, Vlamin V, et al. (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 139 patients with long-term follow-up. J Clin Oncol 11: 1368-1375.

52. Blann AD, Illingworth K, Jayson MI (1993) Mechanisms of endothelial cell damage in vascular disease. J Clin Pathol 46: 295-306.

53. Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, et al. (2002) The role of interferon-alpha in Raynaud's phenomenon and digital necrosis induced by interferon-alpha. Br J Dermatol 147: 481-483.

54. Bachmeyer C, Farge D, Gluckman E, Miclea JM, Aractingi S (1996) Raynaud's phenomenon and digital necrosis induced by interferon-alpha. Arthritis Rheum 39: 299-305.

55. Theofilopoulos AN, Baccala R, Beutler B, Kono D (2004) TYPE I INTERFERONS (a/b) IN IMMUNITY AND AUTOIMMUNITY. Annual Review of Immunology 23: 807-335.

56. York MR, Nagai T, Mangini AJ, Denton CP, et al. (1999) Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 113: 1096-1102.

57. York MR, Nagai T, Mangini AJ, Denton CP, et al. (2000) Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 114: 1096-1102.

58. York MR, Nagai T, Mangini AJ, Denton CP, et al. (2002) Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119: 1096-1102.

59. York MR, Nagai T, Mangini AJ, Denton CP, et al. (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56: 1010-1020.

60. York MR, Nagai T, Mangini AJ, Denton CP, et al. (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56: 1010-1020.

61. York MR, Nagai T, Mangini AJ, Denton CP, et al. (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56: 1010-1020.

62. York MR, Nagai T, Mangini AJ, Denton CP, et al. (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56: 1010-1020.